1,180
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP)

ORCID Icon, , , , , , ORCID Icon, , ORCID Icon & show all
Pages 453-459 | Received 19 Aug 2022, Accepted 01 Nov 2022, Published online: 11 Nov 2022

Figures & data

Figure 1. Enrolment of participant having had eradication treatment for Helicobacter pylori infection in any of the five Nordic countries into the cohort. DE: Denmark; FI: Finland; IC: Iceland; NO: Norway; SE: Sweden. *Only in Sweden, Finland and Denmark.

Figure 1. Enrolment of participant having had eradication treatment for Helicobacter pylori infection in any of the five Nordic countries into the cohort. DE: Denmark; FI: Finland; IC: Iceland; NO: Norway; SE: Sweden. *Only in Sweden, Finland and Denmark.

Figure 2. Inclusion of participants having had eradication treatment for Helicobacter pylori infection in any of the five Nordic countries by calendar year and country.

Figure 2. Inclusion of participants having had eradication treatment for Helicobacter pylori infection in any of the five Nordic countries by calendar year and country.

Table 1. Data availability in the five types of national registries used in each of the five Nordic countries.

Figure 3. Main variables from the national health data registries included in the cohort from the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden).

Figure 3. Main variables from the national health data registries included in the cohort from the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden).

Table 2. Characteristics of cohort participants having had eradication treatment for Helicobacter pylori in any of the five Nordic countries.

Table 3. Distribution of Helicobacter pylori eradication treatment regimens used for inclusion in the cohort from the five Nordic countries, presented as numbers (%).

Supplemental material

Supplemental Material

Download PDF (148.2 KB)

Data availability statement

NordHePEP data can be shared for research purposes upon request by contacting the Chief Investigator, Professor Jesper Lagergren, but may be restricted by and require complimentary permissions from the relevant ethical committees and original data holders.